1. Home
  2. MLAB vs CAPR Comparison

MLAB vs CAPR Comparison

Compare MLAB & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mesa Laboratories Inc.

MLAB

Mesa Laboratories Inc.

HOLD

Current Price

$78.21

Market Cap

441.2M

Sector

Industrials

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$26.07

Market Cap

324.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLAB
CAPR
Founded
1982
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
441.2M
324.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MLAB
CAPR
Price
$78.21
$26.07
Analyst Decision
Hold
Strong Buy
Analyst Count
1
8
Target Price
$67.00
$37.75
AVG Volume (30 Days)
175.6K
5.8M
Earning Date
11-06-2025
11-10-2025
Dividend Yield
0.81%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$245,255,000.00
$11,130,509.00
Revenue This Year
$4.96
N/A
Revenue Next Year
$5.27
$7,736.03
P/E Ratio
N/A
N/A
Revenue Growth
7.39
N/A
52 Week Low
$55.45
$4.30
52 Week High
$155.12
$40.37

Technical Indicators

Market Signals
Indicator
MLAB
CAPR
Relative Strength Index (RSI) 53.16 71.27
Support Level $73.30 $4.30
Resistance Level $80.33 $29.23
Average True Range (ATR) 4.02 3.27
MACD 0.04 1.66
Stochastic Oscillator 59.87 60.24

Price Performance

Historical Comparison
MLAB
CAPR

About MLAB Mesa Laboratories Inc.

Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: